PharmaCyte Biotech, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PMCB research report →
Companypharmacyte.com
PharmaCyte Biotech, Inc. , a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.
- CEO
- Joshua N. Silverman
- IPO
- 2013
- Employees
- 2
- HQ
- Las Vegas, NV, US
Price Chart
Valuation
- Market Cap
- $5.22M
- P/E
- -2.17
- P/S
- 0.00
- P/B
- 0.18
- EV/EBITDA
- 1.16
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -7.69%
- ROIC
- -9.94%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $30.66M · 9084.98%
- EPS
- $3.19 · 277.22%
- Op Income
- $-4,377,862
- FCF YoY
- -38.43%
Performance & Tape
- 52W High
- $1.51
- 52W Low
- $0.63
- 50D MA
- $0.73
- 200D MA
- $0.85
- Beta
- 0.46
- Avg Volume
- 183.09K
Get TickerSpark's AI analysis on PMCB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | WEINSTEIN ROBERT | other | 119,170 |
| Mar 31, 26 | WALKER WAYNE REMELL | other | 119,170 |
| Mar 31, 26 | SCHECHTER JONATHAN | other | 119,170 |
| Mar 31, 26 | Abecassis Michael M | other | 119,170 |
| Jan 7, 26 | Silverman Joshua | buy | 40,000 |
| Jan 6, 26 | Silverman Joshua | buy | 30,000 |
| Jan 5, 26 | Silverman Joshua | buy | 30,000 |
| Jan 7, 26 | SCHECHTER JONATHAN | buy | 20,000 |
| Jan 6, 26 | SCHECHTER JONATHAN | buy | 20,000 |
| Jan 5, 26 | SCHECHTER JONATHAN | buy | 20,000 |
Our PMCB Coverage
We haven't published any research on PMCB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PMCB Report →